WO2014097664A1 - Colon delivery capsule and method for producing same - Google Patents
Colon delivery capsule and method for producing same Download PDFInfo
- Publication number
- WO2014097664A1 WO2014097664A1 PCT/JP2013/063748 JP2013063748W WO2014097664A1 WO 2014097664 A1 WO2014097664 A1 WO 2014097664A1 JP 2013063748 W JP2013063748 W JP 2013063748W WO 2014097664 A1 WO2014097664 A1 WO 2014097664A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chitosan
- mass
- capsule
- layer
- containing layer
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 227
- 238000004519 manufacturing process Methods 0.000 title claims description 34
- 210000001072 colon Anatomy 0.000 title abstract description 58
- 229920001661 Chitosan Polymers 0.000 claims abstract description 166
- 241000894006 Bacteria Species 0.000 claims abstract description 96
- 210000002429 large intestine Anatomy 0.000 claims abstract description 89
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 50
- 229920000615 alginic acid Polymers 0.000 claims abstract description 50
- 239000000783 alginic acid Substances 0.000 claims abstract description 41
- 229960001126 alginic acid Drugs 0.000 claims abstract description 41
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 39
- 239000000463 material Substances 0.000 claims abstract description 36
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 26
- 238000000576 coating method Methods 0.000 claims description 88
- 239000011248 coating agent Substances 0.000 claims description 87
- 229920002494 Zein Polymers 0.000 claims description 80
- 239000005019 zein Substances 0.000 claims description 80
- 229940093612 zein Drugs 0.000 claims description 80
- 239000000758 substrate Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 22
- 238000011049 filling Methods 0.000 claims description 21
- 230000000112 colonic effect Effects 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 abstract description 32
- 210000002784 stomach Anatomy 0.000 abstract description 23
- 239000004480 active ingredient Substances 0.000 abstract description 18
- 239000010410 layer Substances 0.000 description 133
- 239000000243 solution Substances 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 241000186000 Bifidobacterium Species 0.000 description 32
- 239000000843 powder Substances 0.000 description 25
- 230000000968 intestinal effect Effects 0.000 description 21
- 239000002253 acid Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 239000007902 hard capsule Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 238000001035 drying Methods 0.000 description 14
- 239000012530 fluid Substances 0.000 description 12
- 229920001800 Shellac Polymers 0.000 description 11
- -1 gums Polymers 0.000 description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 11
- 239000004208 shellac Substances 0.000 description 11
- 229940113147 shellac Drugs 0.000 description 11
- 235000013874 shellac Nutrition 0.000 description 11
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000001913 cellulose Substances 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 235000010413 sodium alginate Nutrition 0.000 description 8
- 239000000661 sodium alginate Substances 0.000 description 8
- 229940005550 sodium alginate Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000004203 carnauba wax Substances 0.000 description 7
- 235000013869 carnauba wax Nutrition 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 244000063299 Bacillus subtilis Species 0.000 description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 102000014171 Milk Proteins Human genes 0.000 description 5
- 108010011756 Milk Proteins Proteins 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 230000001079 digestive effect Effects 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 235000021239 milk protein Nutrition 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 229920013820 alkyl cellulose Polymers 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 description 3
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000009982 effect on human Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013557 nattō Nutrition 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000010407 ammonium alginate Nutrition 0.000 description 2
- 239000000728 ammonium alginate Substances 0.000 description 2
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 2
- 239000000440 bentonite Chemical class 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical class O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 235000010408 potassium alginate Nutrition 0.000 description 2
- 239000000737 potassium alginate Substances 0.000 description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CCGPUGMWYLICGL-UHFFFAOYSA-N Neburon Chemical compound CCCCN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 CCGPUGMWYLICGL-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical class OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108060006613 prolamin Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Definitions
- the present invention relates to a composition for delivering large intestine containing useful colons and a method for producing the same.
- Oral preparations containing physically protected live bacteria have been developed for the purpose of preventing the inactivation of live bacteria by digestive fluid.
- the protection is too strong, the viable bacteria taken will pass through the large intestine and be excreted, so that a sufficient effect cannot be obtained. Therefore, it is possible to allow live bacteria useful in the large intestine to reach the large intestine that is the active site without being inactivated in the stomach or small intestine, and to deliver live bacteria that have reached the large intestine appropriately on the spot.
- a system is needed.
- Patent Documents 1 and 2 propose a colon delivery system preparation containing an active ingredient coated with a chitosan coating. Since chitosan is a substance that is assimilated by microorganisms in the large intestine, when the preparation reaches the large intestine, the chitosan coating covering the active ingredient is decomposed there and the encapsulated active ingredient is released. However, since chitosan is soluble in acid, the chitosan coating is also degraded by stomach acid. Therefore, in the above-mentioned large intestine delivery system preparation, an acid-resistant coating is further coated on the chitosan coating to prevent the chitosan coating from being decomposed by stomach acid.
- Patent Documents 1 and 2 disclose anionic types such as prolamin proteins such as wheat gliadin and zein, fats and oils, methacrylic acid-methyl methacrylate copolymer, and methacrylic acid-ethyl acrylate copolymer.
- Cellulose derivatives such as acrylic resin, hydroxypropylmethylcellulose acetate succinate, and hydroxypropylmethylcellulose phthalate are described.
- chitosan has a strong water absorption property and easily retains moisture
- the thicker the chitosan coating the more the chitosan coating absorbs water and swells in a watery environment such as the intestine, resulting in a structure of the formulation. It becomes brittle and easily collapses.
- Patent Documents 3 and 4 propose enteric capsules made of a film containing gelatin, polysaccharides such as agar, pectin, gums, and alginic acid. However, these are capsules that are not intended to disintegrate in the stomach but are intended to disintegrate in the small intestine and are not manufactured for substance delivery to the large intestine.
- the large intestine can prevent the invasion of water in the stomach and small intestine, the active ingredient can reach the large intestine without being inactivated or outflowed in the stomach or small intestine, and can rapidly release the active ingredient in the large intestine. A delivery system is awaited.
- the present inventors have encapsulated the active ingredient together with alginic acid and calcium salt, and coated the surface of the capsule encapsulating the active ingredient with a layer containing chitosan having a predetermined thickness. From the above, it has been found that by coating with an enteric base material-containing layer, a composition that has a thin chitosan-containing coating that is difficult to disintegrate in the stomach and intestine and can be delivered to the large intestine without losing the active ingredient can be obtained. The present inventors have also found that the composition makes it possible to deliver and release useful bacteria in the large intestine to the large intestine while maintaining the number of bacteria.
- the present invention comprises a capsule encapsulating useful colons, alginic acid and calcium salt, a chitosan-containing layer covering the capsule, and an enteric substrate-containing layer covering the chitosan-containing layer,
- a composition for large intestine delivery wherein the mass of chitosan in the layer is 0.5% by mass to 8.0% by mass with respect to the mass of the capsule.
- this invention provides the manufacturing method of the said composition for large intestine delivery.
- the capsule containing the useful bacteria is coated with the chitosan-containing layer and the enteric substrate-containing layer, the capsule further contains alginic acid and a calcium salt together with the useful bacteria.
- the capsule is a large intestine delivery system capable of delivering useful bacteria contained in a capsule to the large intestine without deactivation or outflow without disintegrating in the stomach or small intestine.
- the composition for large intestine delivery of the present invention is rapidly degraded in the large intestine to release useful bacteria in the capsule. Therefore, the composition for large intestine delivery of the present invention is useful for improving intestinal flora and intestinal environment.
- composition for large intestine delivery of the present invention comprises a capsule containing useful colons, alginic acid and calcium salt, a chitosan-containing layer covering the capsule, and an enteric substrate-containing layer covering the chitosan-containing layer. .
- composition for large intestine delivery of the present invention When the composition for large intestine delivery of the present invention is taken orally, it is protected from gastric acid by the enteric base material-containing layer, so that the useful colon in the capsule is prevented from being inactivated by gastric acid.
- the enteric base material-containing layer When the composition for large intestine delivery of the present invention moves from the stomach to the small intestine, the enteric base material-containing layer is dissolved by the small intestine digestive fluid, and the chitosan-containing layer is exposed.
- the capsule by having the chitosan-containing layer and the alginic acid and calcium salt inside the capsule, the capsule is prevented from swelling or collapsing due to digestive juice of the small intestine or other moisture, In addition, it protects useful colon bacteria inside the capsule from inactivation and outflow in the small intestine.
- the chitosan-containing layer and the capsule are assimilated and broken down by microorganisms living in the large intestine, and the useful colon in the capsule is released into the large intestine.
- the useful bacteria in the large intestine inside the capsule are released from the large intestine and biological activity while being protected from inactivation and outflow in the stomach and intestine.
- the composition for large intestine delivery of the present invention is useful for improving the intestinal microflora, improving the intestinal environment, or adjusting the intestine.
- the composition for delivery of the large intestine of the present invention contains a capsule that encapsulates useful colons.
- the useful bacteria in the large intestine contained in the capsule may be any microorganism that exhibits a function that is favorable for the living body in the large intestine.
- Examples of the useful colon bacteria include good enteric bacteria such as bifidobacteria, lactic acid bacteria, and natto bacteria.
- the bifidobacteria are not particularly limited as long as they have a useful effect on humans, and can be appropriately selected according to the purpose.
- Examples of Bifidobacteria include Bifidobacterium thermophilum, Bifidobacterium longum, Bifidobacterium bifidum Bifidobium bifidum Um Adrecentis (Bifidobacterium adolescentis), Bifidobacterium infantis (Bifidobacterium infantitis), Bifidobacterium animaris (Bifidobacterium animaris), Bifidobacterium Yudorongamu (Bifidobacterium pseudolongum) bacteria belonging to the Bifidobacterium genus, and the like.
- Bifidobacterium longum B. longum
- Bifidobacterium bifidum B. bifidum
- B. breve Bifidobacterium breve
- Any one of these bifidobacteria may be used alone, or any two or more thereof may be used in combination.
- the lactic acid bacterium is not particularly limited as long as it has a useful effect on humans, and can be appropriately selected according to the purpose.
- lactic acid bacteria include bacteria of the genus Lactobacillus and Streptococcus, such as Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus ), And plant lactic acid bacteria such as lactic acid bacteria RIE strains. Any one of the lactic acid bacteria may be used alone, or two or more of them may
- the natto bacterium is not particularly limited as long as it has a useful effect on humans, and can be appropriately selected according to the purpose.
- Suitable examples of Bacillus natto include Bacillus natto derived from commercially available natto, as well as commercially available Bacillus natto, such as Takahashi bacteria (manufactured by Yuzo Takahashi Laboratory, Yamagata), Naruse bacteria (manufactured by Naruse Fermentation Chemistry Laboratories, Inc., Tokyo, Japan) ), Miyagino fungus (manufactured by Miyagino Natto Factory, Sendai), Asahi fungus (Asahi Kogyo Co., Ltd., Tokyo), Nitto fungus (manufactured by Nitto Yakuhin Kogyo Co., Ltd., Kyoto), Meguro fungus (manufactured by Meguro Research Co., Ltd.) , Osaka). Any one of these Bac
- the large intestine useful bacteria contained in the composition for large intestine delivery of the present invention includes at least one selected from the above-mentioned bifidobacteria, lactic acid bacteria and natto bacteria, and more preferably the above mentioned bifidobacteria. And more preferably at least one selected from the bifidobacteria listed above.
- the useful colon bacteria contained in the composition of the present invention may be live bacteria, dead bacteria, disrupted bacteria thereof, and mixtures thereof, but preferably contain live bacteria. More preferably, the large intestine useful bacteria maintain a high viable count even when filled in the composition of the present invention in the state of viable bacteria and delivered to the large intestine.
- the above-mentioned capsules contained in the composition for large intestine delivery of the present invention contain alginic acid and a calcium salt together with the above-mentioned useful colon.
- the alginic acid reacts with moisture and calcium inside the capsule to form a gel, and forms a wall on the inner wall side of the capsule and around the useful colon. Therefore, if there are alginic acid and calcium salt in the capsule, even if external liquids such as gastric juice and intestinal fluid pass through the chitosan-containing layer and enter the capsule, the capsule swells and collapses, and kills or flows out useful colon bacteria Can be minimized, and the bacteria can be protected from the digestive fluid to prevent the inactivation of the bacteria.
- alginic acid at least one selected from the group consisting of alginic acid, alginates and esters of alginic acid can be selected.
- alginate include monovalent salts such as sodium alginate and potassium alginate; divalent salts such as magnesium alginate; and basic salts such as ammonium alginate.
- alginic acid ester include alginic acid propylene glycol ester. Among these, from the viewpoint of gelation performance and gel properties, alginate is preferable, and sodium alginate is more preferable.
- the calcium salt may be any calcium salt that is allowed to be added to food or medicine, and is selected from the group consisting of calcium citrate, calcium sulfate, calcium lactate, calcium carbonate, calcium chloride, and calcium phosphate, for example. At least one of them. Of these, calcium carbonate is preferred.
- the amount of alginic acid filled in the capsule is preferably 0.1% by mass to 20% by mass, more preferably 1% by mass to 6% by mass in the capsule filling.
- the content of alginic acid in the capsule is preferably 0.1% by mass to 20% by mass, and preferably 1% by mass to 20% by mass with respect to the total mass of useful colon bacteria, or a liquid or solid substance containing the same. 6 mass% is more preferable.
- the amount of the calcium salt in the capsule is preferably 0.02 to 8% by mass, more preferably 0.05 to 3% by mass in the capsule filling.
- the amount of calcium salt in the capsule is preferably 2% by mass to 40% by mass, more preferably 5% by mass to 35% by mass with respect to 100% by mass of alginic acid.
- Each of alginic acid and calcium salt may be separately filled in the capsule, but a mixed powder in which alginic acid and calcium salt are previously mixed in the above ratio may be filled in the capsule.
- capsules that contain useful colon bacteria include capsules that are usually used in the production of pharmaceuticals and foods, and can be, for example, hard capsules, soft capsules, seamless capsules, and the like.
- the capsule is preferably produced from a base material made of gelatin, which has been widely used in the past, or a cellulose derivative obtained by modifying cellulose derived from animals or plants.
- the cellulose derivative include alkyl cellulose (eg, methyl cellulose), hydroxyalkyl cellulose (eg, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, etc.), hydroxyalkyl alkyl cellulose (eg, hydroxypropyl methyl cellulose (HPMC)) , Hydroxyethylmethylcellulose, hydroxyethylethylcellulose, etc.).
- hydroxyalkylalkylcellulose is preferable, and HPMC is more preferable in terms of excellent strength as a capsule and quick dissolution in the large intestine.
- the said base material may be used individually by 1 type, and may use 2 or more types together.
- the above capsules may have a desired shape and size depending on the amount of contents.
- As the size of the capsule for example, generally used sizes such as 00, 0, 1, 2, 3, 3, 4, 5 and the like can be mentioned. , And the like, but are not limited thereto.
- the capsule is filled with the live bacteria of the useful colon.
- the above-mentioned viable bacteria of the large intestine are filled in the capsule, and then the bacteria are further grown in the capsule.
- the form of useful colon in the above capsule is not particularly limited as long as it is a form that can be filled in the capsule, and is appropriately selected according to the type of bacteria and the purpose of use of the composition for large intestine delivery of the present invention. Can do.
- the useful colon can be filled in the capsule in the form of a liquid suspended in an appropriate medium, a dry powder, a solid obtained by mixing the dry powder and hardened oil or the like, and the like.
- a person skilled in the art may select an appropriate method according to the form of the colon bacteria and the type of capsule.
- Useful hard capsules when useful colonic bacteria to be encapsulated are bacteria that are sensitive to high temperatures or are easily inactivated, because capsules can be produced under relatively mild conditions such as temperature conditions. .
- the hard capsule is manufactured by fitting a body part and a cap part manufactured from the above-described base material. What is necessary is just to manufacture the said body part and a cap part according to the manufacturing method of a general hard capsule. For example, the body part and the cap part are soaked in a metal pin molded in the shape of the body part and the cap part in the aqueous solution of the cellulose derivative to attach the cellulose derivative aqueous solution to the surface, and then the pin is pulled up from the liquid. It can be manufactured by drying.
- the body part of the capsules may be filled with useful colon bacteria.
- the filling method include a method of injecting or dripping a liquid substance containing useful colon bacteria into the body portion of the capsule, a method of dropping powdery useful colon bacteria into the capsule body portion while vibrating the feeder, and the like.
- Filling the colons with useful colon can be performed by known capsule filling machines, for example, fully automatic capsule filling machines (for example, Qualicaps Co., Ltd., LIQFIL super 40 type), fully automatic capsule sealing machines (for example, Qualicaps Co., Ltd.). Manufactured by HICAPSEAL 40 type).
- a band seal may be further applied to the fitting portion of the capsule.
- the material for the band seal can be appropriately selected from known materials without particular limitation, and examples thereof include gelatin, cellulose derivatives, polyethylene glycol (PEG), and polyvinyl alcohol (PVA). Examples of the cellulose derivative include the capsule base materials listed above.
- the band seal is made from the same material as the hard capsule material to be sealed.
- the procedure for applying a band seal to the capsule may follow a general method.
- the band seal can be formed by applying an aqueous solution of the above band seal material to the fitting portion of the body portion and the cap portion of the hard capsule and drying.
- the band seal prevents the coating agent from entering the inside of the capsule from the fitting portion when the capsule is coated with the chitosan-containing layer, and smoothes the capsule fitting portion to make a thin and uniform thickness of the chitosan-containing coating.
- band sealing may be performed as necessary, and is not necessarily required as long as fitting and film formation are effective.
- the amount of useful colon bacteria filled in the capsule is preferably 3% by mass to 90% by mass, and more preferably 10% by mass to 60% by mass in the capsule filling. If the filling amount of useful colon bacteria is too small, the intestinal environment improving effect and intestinal regulating effect of the colon delivery composition of the present invention are reduced. On the other hand, if the filling amount of useful colon bacteria is too large, the balance of the intestinal flora may be lost, causing side effects such as diarrhea.
- the concentration of useful colon in the colon when filled into the capsule is preferably 1 ⁇ 10 6 cfu / g or more, and more preferably 1 ⁇ 10 10 cfu / g or more.
- Cfu represents a colony forming unit.
- the large intestine useful bacteria are in the form of a liquid such as a medium suspension, if the bacteria concentration is too high, the viscosity of the liquid will increase and it will be difficult to fill the capsule. After filling, it is preferable to grow the fungus to a desired concentration in the capsule.
- the concentration of useful colon bacteria in the liquid is preferably 1 ⁇ 10 6 cfu / g or more, more preferably 1 ⁇ 10 9 cfu / g to 1 ⁇ 10 12 cfu / g.
- the capsule may further contain other components.
- Other ingredients include: Suspension culture medium used when useful colonic bacteria are converted into liquid; Hardened oil used when useful colon colonies are used as solids; Lactose, starch, dried potato starch and other powders used in some cases; carrageenan, agar, pectin, gum arabic, fine silicon oxide, microcrystalline cellulose, iron salt, hemirose, gelatin, xanthan gum, casein, sodium caseinate, calcium casein , Casein potassium, casein magnesium, milk protein, milk protein peptides, milk protein digest, pullulan, gellan gum, lactoferrin, vegetable oil, hardened oil, sugar, whey, maltodextrin, carmellose sodium, pregelatinized starch, modified starch A component having low water activity or reducing water activity, such as And oligosaccharides, water-soluble dietary fibers, other useful active ingredients for improving the intestinal environment such as water-insoluble dietary fiber. Any one of the other components listed above may be used
- composition for delivery of the large intestine of the present invention was prepared by coating a capsule containing encapsulated useful bacteria of the large intestine obtained by the procedure as described above, alginic acid and a calcium salt with a chitosan-containing layer, and then coating with the chitosan-containing layer.
- the capsule is further produced by coating with an enteric substrate-containing layer.
- a capsule containing an active ingredient is coated with a chitosan-containing layer.
- chitosan contained in the chitosan-containing layer there are no particular restrictions on the properties of chitosan contained in the chitosan-containing layer, such as the degree of deacetylation and molecular weight, but if the degree of deacetylation is 60 mol% or more, it is dissolved in the acid solution during the preparation of the coating solution. Is preferable from the viewpoints of film property and film forming property.
- the chitosan content in the chitosan-containing layer (dried product) may be 25% by mass or more, preferably 25% by mass to 85% by mass, more preferably 35% by mass to 80% by mass in the total mass.
- the chitosan-containing layer is preferably a layer containing chitosan and zein (hereinafter also referred to as chitosan-zein layer).
- chitosan-zein layer a layer containing chitosan and zein layer
- the film-forming property is improved as compared with the coating, and it has higher water resistance, and prevents swelling and disintegration of the composition of the present invention due to water absorption in the intestine.
- Zein is a water-insoluble protein extracted from corn and is also called corn protein.
- the purified zein is usually a white to pale yellow powder.
- Zein is hardly soluble in water and ethanol, but is easily soluble in hydrous ethanol and acetone, and is dissolved by the action of a strongly alkaline region or a proteolytic enzyme.
- Zein is highly safe and is often used as an additive for foods and pharmaceuticals.
- Zein has been used in conventional chitosan coating preparations, but is generally separately coated on the upper layer of the chitosan coating as a gastric acid resistant coating (for example, Patent Document 1), and a chitosan-containing layer that is an enteric-soluble layer Was not added.
- a gastric acid resistant coating for example, Patent Document 1
- the zein content in the chitosan-zein layer may be 0.5 to 100 parts by mass, preferably 5 to 80 parts by mass with respect to 100 parts by mass of chitosan.
- the zein content is less than the above-mentioned amount, the film-forming property is lowered, and the water resistance of the obtained coating film is lowered to be easily disintegrated.
- the content of zein is larger than the above amount, the obtained chitosan film becomes too hard and the disintegration property is deteriorated.
- the chitosan-containing layer or chitosan-zein layer is prepared by dissolving the chitosan or chitosan and zein in a liquid by a known method to prepare a coating solution, and attaching the obtained coating solution to the surface of the capsule and then drying it.
- Chitosan can be dissolved in an acidic aqueous solution.
- the acid to be coexisted in the acidic aqueous solution include inorganic acids and organic acids, and organic acids are preferable because inorganic acids have a strong interaction with chitosan.
- the organic acid is not particularly limited, but formic acid, acetic acid, lactic acid, sulfamic acid, propionic acid, and trichloroacetic acid are preferable examples because they have sufficient volatility at normal pressure.
- acetic acid is more preferable because it is inexpensive, easy to handle, and has little influence on the human body even if it remains in the chitosan-containing layer or chitosan-zein layer.
- the pH of the acidic aqueous solution may be in the range of 3.5 to 6.5.
- the pH of the acidic aqueous solution is less than 3.5, an acid may remain in the chitosan-containing layer or the chitosan-zein layer, and the water resistance of the resulting coating may be lowered.
- the pH of the solution is higher than 6.5, the solubility of chitosan decreases.
- Zein is difficult to dissolve in water, so handling with an organic solvent makes it easy to handle.
- an organic solvent to the acidic aqueous chitosan solution prepared above and dissolve zein therein.
- zein may be dissolved in a water / ethanol solution and then mixed with a chitosan solution.
- the organic solvent include alcohols such as methanol and ethanol, ketones such as acetone, and ethers. Ethanol is preferable from the viewpoint of interaction with chitosan.
- the concentration of chitosan may be about 0.05% to 12% by mass, preferably 1% to 5% by mass, based on the total mass of the solution. Degree.
- the concentration of zein in the solution may be about 0.01% to 12% by mass of the total mass of the solution, preferably about 0.1% to 5% by mass, or 100 parts by mass of chitosan. 0.5 parts by mass to 100 parts by mass, preferably 5 parts by mass to 80 parts by mass based on the mass.
- the concentration of ethanol in the solution can be 40% to 90% by weight, preferably 50% to 80% by weight of the total weight of the solution.
- the viscosity of the coating solution is preferably 5 to 500 mPa ⁇ s at room temperature.
- the viscosity in the present specification is a value measured by a C-type viscometer (available from TOKIMEC INC).
- the coating solution containing chitosan or chitosan and zein may further contain other components that can be contained in the chitosan-containing layer or chitosan-zein layer.
- the other components include, but are not limited to, a film-forming substrate, a filler, and a plasticizer.
- a film-forming base material is added to the coating solution, it becomes easier to form a film of the chitosan-containing layer or the chitosan-zein layer.
- the substrate has an emulsifying power in addition to the film forming property.
- Examples of the base material having a film-forming property and emulsifying power include water-soluble celluloses such as alkyl celluloses (for example, methyl cellulose and ethyl cellulose), hydroxyalkyl celluloses (for example, hydroxyethyl cellulose and hydroxypropyl cellulose), hydroxyalkyl alkyl celluloses (for example) For example, hydroxypropyl methylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose, etc.); pullulan, gum arabic, carrageenan, fine silicon oxide, microcrystalline cellulose, hemirose, agar, gelatin, xanthan gum, casein, milk protein, oligosaccharide, maltodextrin, Carmellose sodium, starch, pregelatinized starch, modified starch, polyethylene glycol, polyvinylpyrrolidone (PVP) Corn fiber, gelling agents such as guar gum and pectin, thickeners or water-soluble poly
- the filler is not particularly limited, and examples thereof include talc, precipitated calcium carbonate, silicon dioxide, microcrystalline cellulose, reduced maltose, bentonite, and a metal salt of an organic acid having 10 or more carbon atoms.
- the filler content in the coating solution may be 0.06 parts by mass to 60 parts by mass with respect to 100 parts by mass of chitosan in the solution.
- Plasticizers include glycerin, diglycerin, diethylene glycol, propylene glycol, triethylene glycol, polyethylene glycol, sorbitol, mannitol and other polyhydric alcohols, glycerin fatty acid esters, polyglycerin fatty acid esters, sorbitan fatty acid esters, lecithin derivatives, organic acid monoglycerides , Medium chain fatty acid triglycerides, sucrose esters and the like.
- the plasticizer content in the coating solution may be 0.05 to 100 parts by mass with respect to 100 parts by mass of chitosan in the solution.
- the chitosan-containing layer or chitosan-zein layer for coating the capsule containing useful colon in the large intestine delivery composition of the present invention is a means for applying, spraying, immersing, etc. the above-mentioned chitosan or a coating solution containing chitosan and zein. Can be formed by attaching to the surface of the capsule and then drying.
- a chitosan-containing film or a chitosan- and zein-containing film can be produced by blending together a composition containing chitosan or chitosan and zein at the time of soft capsule film formation and drying.
- Capsule coating is usually performed using a coating apparatus, for example, a breathable coating apparatus (for example, POWREC Coater: manufactured by POWREC Co., Ltd.), a fluidized bed granulation coating apparatus (for example, flow coater, manufactured by Freund Sangyo Co., Ltd.). , Centrifugal rolling granulation coating apparatus (for example, CF granulator, Granurex, manufactured by Freund Sangyo Co., Ltd.), composite granulation coating apparatus (for example, Spiraflow, manufactured by Freund Sangyo Co., Ltd.), sugar coating film coating apparatus (for example, , High coater, aqua coater: manufactured by Freund Sangyo Co., Ltd.) and the like.
- a coating apparatus for example, a breathable coating apparatus (for example, POWREC Coater: manufactured by POWREC Co., Ltd.), a fluidized bed granulation coating apparatus (for example, flow coater, manufactured by Freund Sangyo Co., Ltd.).
- the coating solution containing chitosan or chitosan and zein is applied to the surface of the capsule using a spray or the like while supplying and exhausting dry air.
- a chitosan-containing layer or chitosan-zein layer can be formed on the surface of the capsules by spraying and then drying to remove the acid.
- the air supply temperature in the step of forming (coating) the chitosan-containing layer or chitosan-zein layer using the above apparatus is not particularly limited, but is preferably 40 to 90 ° C. If the supply air temperature is less than 40 ° C., the acid is not sufficiently removed, and thus water resistance is not sufficiently imparted to the coating of the chitosan-containing layer or the chitosan-zein layer. On the other hand, when the supply air temperature exceeds 90 ° C., the chitosan-containing layer or the chitosan-zein layer has problems in appearance such as coloring and deformation, and an excessive heat load is applied to useful colonic bacteria in the capsule. Absent.
- the exhaust temperature in the step of forming a chitosan-containing layer or chitosan-zein layer using the above apparatus may be 30 ° C. to 85 ° C., and can be appropriately selected according to the composition of the coating solution.
- the thickness of the chitosan-containing layer or chitosan-zein layer in the composition for large intestine delivery of the present invention is converted to the chitosan mass in the chitosan-containing layer or chitosan-zein layer, with respect to the mass of the capsule containing the contents, 0.5% by mass or more, preferably 0.5% by mass to 8.0% by mass, more preferably 0.8% by mass to 6.0% by mass, and still more preferably 0.8% by mass to 4.0% by mass. It is.
- the chitosan mass is less than 0.5% by mass of the capsule mass, the chitosan-containing layer or chitosan-zein layer is thin, so that the enteric base material-containing layer soon collapses in the small intestine.
- the layer may also collapse, and capsules containing useful colon can not be delivered to the large intestine.
- the chitosan mass exceeds 8.0% by mass of the capsule mass, it takes time to form the chitosan-containing layer or the chitosan-zein layer, and useful colon bacteria in the capsule are heated for a long time. Therefore, it is not preferable.
- a coating of an enteric base material-containing layer is further formed on the chitosan-containing layer or chitosan-zein layer.
- the material of the enteric base material-containing layer is not particularly limited as long as it is acid-resistant and difficult to dissolve in the stomach but dissolves in the small intestine, so-called enteric base material.
- the enteric substrate include carboxymethyl ethyl cellulose (CMEC), methacrylic acid copolymer, hypromellose phthalate (HPMCP), zein, alcohol shellac, aqueous shellac and the like.
- CMEC carboxymethyl ethyl cellulose
- HPPMCP hypromellose phthalate
- zein zein
- alcohol shellac aqueous shellac and the like.
- methacrylic acid copolymers, zein, HPMCP, and alcohol shellac are preferable because they are highly effective in preventing water from entering the capsule.
- the enteric substrate-containing layer may further contain other components other than the enteric substrate.
- the other components are not particularly limited as long as the acid resistance of the enteric substrate-containing layer is not impaired, but water-insoluble additives are preferable.
- water-insoluble additives include talc, bentonite, and metal salts of organic acids having 10 or more carbon atoms.
- the coating of the enteric substrate-containing layer can be formed by the same procedure as that for the chitosan-containing layer or chitosan-zein layer described above. That is, the coating solution containing the enteric base material is attached to the surface of the capsule coated with the chitosan-containing layer or chitosan-zein layer by means of application, spraying, dipping, etc., and then dried to contain the enteric base material. A layer can be formed.
- the concentration of the enteric substrate in the coating solution containing the enteric substrate is preferably 0.1% by mass to 12% by mass with respect to the total mass of the solution.
- the viscosity of the enteric base solution is preferably about 10 mPa ⁇ s to 500 mPa ⁇ s at room temperature.
- the air supply temperature of the coating apparatus in the layer forming step is preferably 30 ° C. to 80 ° C., and the exhaust temperature is preferably 30 ° C. to 80 ° C. If the supply air temperature is less than 30 ° C., the drying efficiency is low and the coating time is long, which is not preferable. On the other hand, if the supply air temperature is too high, an excessive heat load is applied to the useful colon in the capsule, which is not preferable.
- the thickness of the enteric substrate-containing layer in the composition for delivering large intestine of the present invention can be appropriately selected according to the shape, size, mass, etc. of the capsule to be coated.
- the thickness of the enteric substrate-containing layer is preferably 0.5% by mass to 10.0% with respect to the mass of the capsule containing the content, in terms of the mass of the enteric substrate in the layer. % By mass, more preferably 0.5% by mass to 7.0% by mass, and still more preferably 0.8% by mass to 5% by mass.
- the thickness of the enteric substrate-containing layer is less than 0.5% by mass of the enteric substrate, the thin enteric substrate-containing layer rapidly disintegrates in the small intestine, so that the chitosan-containing layer or chitosan-zein The layer may also collapse in the small intestine and capsules containing useful colon bacteria may not be delivered to the large intestine.
- the thickness of the enteric substrate-containing layer exceeds 10.0% by mass, it takes time to form the enteric substrate-containing layer, and the large intestine useful bacteria in the capsule are heated for a long time. This is not preferable.
- composition for large intestine delivery of the present invention comprises, in addition to the above-mentioned capsule containing useful colon bacteria, alginic acid and calcium salt, a chitosan-containing layer or chitosan-zein layer, an enteric base material-containing layer, and further the enteric group.
- a chitosan-containing layer or chitosan-zein layer an enteric base material-containing layer, and further the enteric group.
- composition for large intestine delivery of the present invention can protect the components inside the capsule from inactivation and outflow in the small intestine and can be released into the large intestine. Therefore, the composition for large intestine delivery of the present invention can be applied to large intestine delivery of active ingredients that are easily inactivated in the small intestine and active ingredients that are easily absorbed in the small intestine and difficult to reach the large intestine, in addition to the above-mentioned useful bacteria for the large intestine. I can do it.
- Such active ingredients include, for example, vitamin C, vitamins B1, B2, B6, B12, water-soluble vitamins such as niacin (nicotinic acid) and folic acid, pharmacological ingredients intended to be released in the large intestine, and the like Can be mentioned.
- the active ingredients can be applied to the composition for delivery of the large intestine of the present invention alone or together with the above useful colonic bacterium. Therefore, the composition for large intestine delivery of the present invention may contain the above-mentioned active ingredient in a capsule instead of or in addition to the above-mentioned useful colon.
- the composition for large intestine delivery of the present invention is a composition for oral administration.
- the composition for large intestine delivery of the present invention is an orally administered composition for improving the intestinal environment of an animal or for adjusting the intestine of an animal.
- the composition for large intestine delivery of the present invention may be provided by being added to food or feed, or may be provided as a pharmaceutical or a supplement.
- the composition for large intestine delivery of the present invention can be a pharmaceutical or supplement for improving intestinal environment or intestinal regulation.
- composition, medicament or supplement for improving the intestinal environment or adjusting the intestine is coated with a chitosan-containing layer or chitosan-zein layer on a capsule containing useful colonic bacteria, alginic acid and calcium salt in the procedure described above. It is manufactured by coating with an enteric substrate-containing layer from above.
- the composition for large intestine delivery of the present invention can be used for the improvement of the intestinal environment or the manufacture of a pharmaceutical or supplement for intestinal regulation.
- composition, medicine or supplement for large intestine delivery of the present invention is given orally to an animal to improve the intestinal bacterial flora and intestinal environment of the animal or bring about an intestinal regulating effect on the animal.
- animals that can be provided with the composition for large intestine delivery of the present invention include humans and non-human animals, and examples of non-human animals include non-human primates, cows, pigs, sheep, goats, dogs, cats, rodents. Etc.
- Capsule containing useful colon Capsule No. 1 Bifidobacteria live powder (Morinaga Milk Industry Co., Ltd., Morinaga Bifidobacterium powder) 520 g, dried potato starch (Matsuya Chemical Co., Ltd.) 550 g, milk protein (Nippon Shinyaku Co., Ltd.) 390 g, sodium alginate (Co., Ltd.) 30 g of Kimika) and 10 g of calcium carbonate (Shiraishi Kogyo Co., Ltd.) were uniformly triturated and mixed to obtain a powder for capsule filling.
- hydroxypropylmethylcellulose (HPMC) capsules As hard capsules filled with the bacteria-containing powder, hydroxypropylmethylcellulose (HPMC) capsules (Qualicaps Co., Ltd., Quali-V (R) -N, No. 3, capsule mass: 46 mg) were used.
- HPMC hydroxypropylmethylcellulose
- the bifidobacteria-containing powder and hard capsules were set in a capsule filling machine (LIQFIL super 40 type, manufactured by Qualicaps Co., Ltd.), and 230 mg of the bifidobacteria-containing powder was filled into the hard capsules.
- the concentration of bifidobacteria per capsule was 1.1 ⁇ 10 10 cfu / g.
- capsule mass 46 mg
- the bifidobacteria-containing powder and hard capsules were set in a capsule filling machine (LIQFIL super 40 type, manufactured by Qualicaps Co., Ltd.), and 230 mg of the bifidobacteria-containing powder was filled into the hard capsules.
- the concentration of bifidobacteria per capsule was 1.0 ⁇ 10 10 cfu / g.
- Bifidobacteria live powder (Morinaga Milk Industry Co., Ltd., Morinaga Bifidobacterium powder) 520 g was uniformly triturated with 980 g of dried potato starch (Matsuya Chemical Co., Ltd.) and mixed to obtain a powder for capsule filling.
- hydroxypropylmethylcellulose (HPMC) capsules As hard capsules filled with the bacteria-containing powder, hydroxypropylmethylcellulose (HPMC) capsules (Qualicaps Co., Ltd., Quali-V (R) -N, No. 3, capsule mass: 46 mg) were used.
- the bifidobacteria-containing powder and hard capsules were set in a capsule filling machine (LIQFIL super 40 type, manufactured by Qualicaps Co., Ltd.), and 230 mg of the bifidobacteria-containing powder was filled into the hard capsules.
- the concentration of bifidobacteria per capsule was 1.0 ⁇ 10 10 cfu / g.
- the coating was performed using a film coater high coater mini-type pan (Freund Sangyo Co., Ltd.) at a constant drying temperature (65 ° C.).
- the chitosan-zein layer was formed so that the chitosan mass relative to the capsule mass was about 1.4% by mass.
- a part of the produced capsule was extracted, and the composition of the chitosan-zein layer was examined.
- the capsule coated with the chitosan-zein layer was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass).
- a small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
- the capsule coated with the chitosan layer was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass).
- shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass).
- a small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
- the capsule coated with the chitosan layer was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass).
- shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass).
- a small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
- Capsule No. containing capsules useful in large intestine produced in Reference Example 3 3 were prepared using the solution No. 3 prepared with the composition shown in Table 1. 4 (alginate and chitosan-containing coating solution) was used to coat the chitosan-containing layer. The coating was performed using a film coating apparatus high coater mini-type pan (Freund Sangyo Co., Ltd.) with the drying temperature of the coating apparatus kept constant (80 ° C.). The chitosan-containing layer was formed so that the chitosan mass relative to the capsule mass was about 1.7% by mass. A part of the produced capsule was extracted, and the composition of the chitosan layer was examined.
- the capsule coated with the chitosan layer was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass).
- shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass).
- a small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
- the zein solution used for the zein coating was prepared by dissolving zein (Kobayashi Twein DP (manufactured by Kobayashi Fragrance Co., Ltd.)) in a 60% ethanol solution to a concentration of 6% by mass, and using glycerin (manufactured by Kao Corporation) as a plasticizer. It was prepared by adding 30% by mass to zein.
- the capsule coated with the chitosan layer and zein was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass).
- shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass).
- a small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
- ⁇ Test Example 1> (Residual acetic acid amount / membrane strength test) A part of each capsule obtained was dissolved, and the remaining acetic acid amount was measured by HPLC using an Inertsil ODS-4 column. As sought. The membrane strength of the capsules was measured as a pressure at which the capsules were broken with a pressurization type measuring device (load measuring device manufactured by Minebea Co., Ltd.).
- the disintegration properties of the multi-coated capsules of Production Examples 1 to 12 in the stomach, small intestine and large intestine were examined.
- the disintegration test was performed using 6 capsules each and using a disintegration test apparatus of Japanese Pharmacopoeia.
- the capsule is moved up and down in a pH 1.2 solution (stomach solution) for 60 minutes without an auxiliary board, the disintegrated capsule is removed, and then in a pH 6.8 solution (small intestine solution) for 120 minutes.
- the capsule which collapsed was moved up and down, the disintegrated capsule was removed, and then moved up and down for 120 minutes in a pH 3.5 solution (large intestine assumed liquid) under the condition using an auxiliary board.
- Capsules containing alginic acid and calcium salt in the capsules of Production Examples 1 to 2, 4 to 5 and 7 to 8 and coated with a chitosan-containing layer have high membrane strength, and disintegration in the assumed solution of the stomach and small intestine While it was highly resistant, it disintegrated well in the assumed large intestine.
- the capsules of Production Examples 1 and 2 coated with a layer containing chitosan and zein further improved the resistance to disintegration in the assumed liquid of the stomach and small intestine, and the amount of acid remaining in the chitosan-containing layer decreased. .
- ⁇ Test Example 2> Using the multi-coated capsules of Production Examples 1, 3, 4, 6, 7, and 9, the remaining viable count of bifidobacteria in the capsule after immersion in the assumed gastric fluid was examined. A disintegration test was carried out for 60 minutes in the assumed gastric fluid at pH 1.2 in the same manner as in Test Example 1, and the number of remaining bifidobacteria in the capsule was measured for the capsules that remained undisintegrated. The number of remaining bacteria is determined by suspending the powder extracted from the capsule in a dilute solution, aseptically diluting it to a predetermined concentration by a dilution method, and then inoculating this bacterial solution on the surface of the anaerobic BL agar medium.
- the capsule of Production Example 3 having a chitosan-zein layer coating but containing no alginic acid and calcium salt in the capsule maintained a high viable count after the test with the assumed gastric solution, but the test with the assumed small intestine solution Later, the number of viable bacteria decreased significantly.
- Example 3 Using the capsule of useful colon-containing bacteria (capsule No. 1) of Reference Example 1, the amount of zein added was confirmed. A chitosan-zein-containing coating solution prepared with the composition described in Table 4 was used to coat the chitosan-zein layer. The coating was performed using a film coater high coater mini-type pan (Freund Sangyo Co., Ltd.) at a constant drying temperature (65 ° C.). The chitosan-zein layer was formed so that the chitosan mass relative to the capsule mass was about 1.4% by mass.
- the capsule coated with the chitosan-zein layer was further coated with shellac, which is an acid-resistant substrate (about 1.2% by mass with respect to the capsule mass).
- shellac is an acid-resistant substrate (about 1.2% by mass with respect to the capsule mass).
- Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
- Each manufactured capsule was evaluated in the same procedure as in Test Example 1. The results are shown in Table 5. In Production Example 18, a test was not performed because a precipitate was generated in the coating solution.
- Example 4 Using the capsule of useful colon-containing bacteria (capsule No. 1) of Reference Example 1, the effect of the thickness of the chitosan-containing layer on the capsule disintegration property was confirmed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
Description
また本発明は、上記大腸送達用組成物の製造方法を提供する。 That is, the present invention comprises a capsule encapsulating useful colons, alginic acid and calcium salt, a chitosan-containing layer covering the capsule, and an enteric substrate-containing layer covering the chitosan-containing layer, Provided is a composition for large intestine delivery, wherein the mass of chitosan in the layer is 0.5% by mass to 8.0% by mass with respect to the mass of the capsule.
Moreover, this invention provides the manufacturing method of the said composition for large intestine delivery.
(カプセルNo.1)
ビフィズス菌の生菌粉末(森永乳業株式会社製、森永ビフィズス菌末)520gを、乾燥馬鈴薯でんぷん(松谷化学工業株式会社製)550g、乳蛋白(日本新薬株式会社製)390g、アルギン酸ナトリウム(株式会社キミカ製)30g、炭酸カルシウム(白石工業株式会社製)10gで均一に倍散し、混合し、カプセル充填用の粉末とした。
菌含有粉末を充填するハードカプセルとして、ヒドロキシプロピルメチルセルロース(HPMC)カプセル(クオリカプス株式会社製、クオリ-V(R)-N、3号、カプセル質量:46mg)を用いた。
カプセル充填機(クオリカプス株式会社製、LIQFIL super 40型)に、上記ビフィズス菌含有粉末とハードカプセルとをセットし、ハードカプセル内にビフィズス菌含有粉末を230mg充填した。1カプセルあたりのビフィズス菌濃度は、1.1×1010cfu/gであった。 <Reference Example 1> Capsule containing useful colon (Capsule No. 1)
Bifidobacteria live powder (Morinaga Milk Industry Co., Ltd., Morinaga Bifidobacterium powder) 520 g, dried potato starch (Matsuya Chemical Co., Ltd.) 550 g, milk protein (Nippon Shinyaku Co., Ltd.) 390 g, sodium alginate (Co., Ltd.) 30 g of Kimika) and 10 g of calcium carbonate (Shiraishi Kogyo Co., Ltd.) were uniformly triturated and mixed to obtain a powder for capsule filling.
As hard capsules filled with the bacteria-containing powder, hydroxypropylmethylcellulose (HPMC) capsules (Qualicaps Co., Ltd., Quali-V (R) -N, No. 3, capsule mass: 46 mg) were used.
The bifidobacteria-containing powder and hard capsules were set in a capsule filling machine (LIQFIL super 40 type, manufactured by Qualicaps Co., Ltd.), and 230 mg of the bifidobacteria-containing powder was filled into the hard capsules. The concentration of bifidobacteria per capsule was 1.1 × 10 10 cfu / g.
ビフィズス菌の生菌粉末(森永乳業株式会社製、森永ビフィズス菌末)520gを乾燥馬鈴薯でんぷん(松谷化学工業株式会社製)940g、アルギン酸ナトリウム(株式会社キミカ製)30g、炭酸カルシウム(白石工業株式会社製)10gで均一に倍散し、混合し、カプセル充填用の粉末とした。
菌含有粉末を充填するハードカプセルとして、ヒドロキシプロピルメチルセルロース(HPMC)カプセル(クオリカプス株式会社製、クオリ-V(R)-N、3号、カプセル質量:46mg)を用いた。
カプセル充填機(クオリカプス株式会社製、LIQFIL super 40型)に、上記ビフィズス菌含有粉末とハードカプセルとをセットし、ハードカプセル内にビフィズス菌含有粉末を230mg充填した。1カプセルあたりのビフィズス菌濃度は、1.0×1010cfu/gであった。 (Capsule No. 2)
Bifidobacteria live bacteria powder (Morinaga Milk Industry Co., Ltd., Morinaga Bifidobacterium powder) 520 g, dried potato starch (Matsuya Chemical Co., Ltd.) 940 g, sodium alginate (Kimika Co., Ltd.) 30 g, calcium carbonate (Shiraishi Kogyo Co., Ltd.) (Product made) 10 g of powder was uniformly dispersed and mixed to obtain a powder for capsule filling.
As hard capsules filled with the bacteria-containing powder, hydroxypropylmethylcellulose (HPMC) capsules (Qualicaps Co., Ltd., Quali-V (R) -N, No. 3, capsule mass: 46 mg) were used.
The bifidobacteria-containing powder and hard capsules were set in a capsule filling machine (LIQFIL super 40 type, manufactured by Qualicaps Co., Ltd.), and 230 mg of the bifidobacteria-containing powder was filled into the hard capsules. The concentration of bifidobacteria per capsule was 1.0 × 10 10 cfu / g.
ビフィズス菌の生菌粉末(森永乳業株式会社製、森永ビフィズス菌末)520gを乾燥馬鈴薯でんぷん(松谷化学工業株式会社製)980gで均一に倍散し、混合し、カプセル充填用の粉末とした。
菌含有粉末を充填するハードカプセルとして、ヒドロキシプロピルメチルセルロース(HPMC)カプセル(クオリカプス株式会社製、クオリ-V(R)-N、3号、カプセル質量:46mg)を用いた。
カプセル充填機(クオリカプス株式会社製、LIQFIL super 40型)に、上記ビフィズス菌含有粉末とハードカプセルとをセットし、ハードカプセル内にビフィズス菌含有粉末を230mg充填した。1カプセルあたりのビフィズス菌濃度は、1.0×1010cfu/gであった。 (Capsule No. 3)
Bifidobacteria live powder (Morinaga Milk Industry Co., Ltd., Morinaga Bifidobacterium powder) 520 g was uniformly triturated with 980 g of dried potato starch (Matsuya Chemical Co., Ltd.) and mixed to obtain a powder for capsule filling.
As hard capsules filled with the bacteria-containing powder, hydroxypropylmethylcellulose (HPMC) capsules (Qualicaps Co., Ltd., Quali-V (R) -N, No. 3, capsule mass: 46 mg) were used.
The bifidobacteria-containing powder and hard capsules were set in a capsule filling machine (LIQFIL super 40 type, manufactured by Qualicaps Co., Ltd.), and 230 mg of the bifidobacteria-containing powder was filled into the hard capsules. The concentration of bifidobacteria per capsule was 1.0 × 10 10 cfu / g.
(溶液No.1:キトサン-ゼイン含有コーティング溶液)
精製水に酢酸を加えpHを約4の酸性水を調製した。この酸性水に、脱アセチル化度が80モル%以上であるキトサン(フローナックC:日本水産株式会社製)を溶解した。得られたキトサン溶解液に、グリセリン(花王株式会社製)を添加し、次いでエタノールを加え、さらにゼイン(小林ツエインDP(小林香料株式会社製))を添加した。キトサンの最終濃度が2.5質量%、ゼインの最終濃度が0.5質量%になるように精製水で調整し、キトサンとゼインを含有するコーティング溶液を調製した。 Reference Example 2 Coating Solution (Solution No. 1: Chitosan-Zein-Containing Coating Solution)
Acetic acid was added to purified water to prepare acidic water having a pH of about 4. In this acidic water, chitosan having a degree of deacetylation of 80 mol% or more (Flownack C: manufactured by Nihon Suisan Co., Ltd.) was dissolved. To the obtained chitosan solution, glycerin (manufactured by Kao Corporation) was added, ethanol was added, and zein (Kobayashi Twein DP (manufactured by Kobayashi Fragrance Co., Ltd.)) was further added. The coating solution containing chitosan and zein was prepared by adjusting with purified water so that the final concentration of chitosan was 2.5% by mass and the final concentration of zein was 0.5% by mass.
参考例2と同様にして、ただしエタノールおよびゼインを添加せずに、グリセリン脂肪酸エステル(阪本薬品工業株式会社製:デカグリセリンモノエステル)をキトサン100質量部に対して50質量部となるよう添加し、キトサン含有コーティング液を調整した。 (Solution No. 2: Chitosan-containing coating solution)
As in Reference Example 2, but without adding ethanol and zein, glycerin fatty acid ester (Sakamoto Yakuhin Kogyo Co., Ltd .: decaglycerin monoester) was added to 50 parts by mass with respect to 100 parts by mass of chitosan. A chitosan-containing coating solution was prepared.
参考例2と同様にして、ただしエタノールおよびゼインを添加せずにキトサン含有コーティング液を調整した。 (Solution No. 3: Chitosan-containing coating solution)
A chitosan-containing coating solution was prepared in the same manner as in Reference Example 2 except that ethanol and zein were not added.
参考例2と同様にして、ただしエタノールおよびゼインを添加せずに、アルギン酸ナトリウム(株式会社キミカ製)をキトサン100質量部に対して0.5質量部となるよう添加し、キトサンおよびアルギン酸ナトリウム含有コーティング液を調整した。
<製造例1~3>
参考例1で製造した大腸有用菌含有カプセルNo.1~3を、表1記載の組成で調製した溶液No.1(キトサン-ゼイン含有コーティング溶液)を用いて、キトサン-ゼイン層で被覆した。被覆は、フィルムコーティング装置ハイコーターミニ型パン(フロイント産業株式会社製)を用いて、コーティング装置の乾燥温度を一定(65℃)にして行った。カプセル質量に対するキトサン質量が約1.4質量%になるようにキトサン-ゼイン層を形成した。製造したカプセルの一部を抜き出し、キトサン-ゼイン層の組成を調べた。
次いで、キトサン-ゼイン層で被覆したカプセルをさらに腸溶性基材であるセラックで被覆した(カプセル質量に対して約1.2質量%)。得られたカプセルの表面にカルナウバロウを微量塗布し、多重コーティングカプセルを製造した。 (Solution No. 4: Coating solution containing chitosan and sodium alginate)
In the same manner as in Reference Example 2, but without adding ethanol and zein, sodium alginate (Kimika Co., Ltd.) was added to 0.5 parts by mass with respect to 100 parts by mass of chitosan, containing chitosan and sodium alginate. The coating solution was adjusted.
<Production Examples 1 to 3>
Useful colon-containing capsule No. 1 produced in Reference Example 1 1 to 3 were prepared using solution Nos. 1 prepared with the compositions shown in Table 1. 1 (chitosan-zein containing coating solution) was used to coat with the chitosan-zein layer. The coating was performed using a film coater high coater mini-type pan (Freund Sangyo Co., Ltd.) at a constant drying temperature (65 ° C.). The chitosan-zein layer was formed so that the chitosan mass relative to the capsule mass was about 1.4% by mass. A part of the produced capsule was extracted, and the composition of the chitosan-zein layer was examined.
Next, the capsule coated with the chitosan-zein layer was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass). A small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
参考例1で製造した大腸有用菌含有カプセルNo.1~3を、表1記載の組成で調製した溶液No.2(キトサン含有コーティング溶液)を用いて、キトサン含有層で被覆した。被覆は、フィルムコーティング装置ハイコーターミニ型パン(フロイント産業株式会社製)を用いて、コーティング装置の乾燥温度を一定(80℃)にして行った。カプセル質量に対するキトサン質量が約1.7質量%になるようにキトサン層を形成した。製造したカプセルの一部を抜き出し、キトサン層の組成を調べた。
次いで、キトサン層で被覆したカプセルをさらに腸溶性基材であるセラックで被覆した(カプセル質量に対して約1.2質量%)。得られたカプセルの表面にカルナウバロウを微量塗布し、多重コーティングカプセルを製造した。 <Production Examples 4 to 6>
Useful colon-containing capsule No. 1 produced in Reference Example 1 1 to 3 were prepared using solution Nos. 1 prepared with the compositions shown in Table 1. 2 (chitosan-containing coating solution) was used to coat the chitosan-containing layer. The coating was performed using a film coating apparatus high coater mini-type pan (Freund Sangyo Co., Ltd.) with the drying temperature of the coating apparatus kept constant (80 ° C.). The chitosan layer was formed so that the chitosan mass with respect to the capsule mass was about 1.7 mass%. A part of the produced capsule was extracted, and the composition of the chitosan layer was examined.
Next, the capsule coated with the chitosan layer was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass). A small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
参考例1で製造した大腸有用菌含有カプセルNo.1~3を、表1記載の組成で調製した溶液No.3(キトサン含有コーティング溶液)を用いて、キトサン含有層で被覆した。被覆は、フィルムコーティング装置ハイコーターミニ型パン(フロイント産業株式会社製)を用いて、コーティング装置の乾燥温度を一定(80℃)にして行った。カプセル質量に対するキトサン質量が約1.7質量%になるようにキトサン含有層を形成した。製造したカプセルの一部を抜き出し、キトサン層の組成を調べた。
次いで、キトサン層で被覆したカプセルをさらに腸溶性基材であるセラックで被覆した(カプセル質量に対して約1.2質量%)。得られたカプセルの表面にカルナウバロウを微量塗布し、多重コーティングカプセルを製造した。 <Production Examples 7 to 9>
Useful colon-containing capsule No. 1 produced in Reference Example 1 1 to 3 were prepared using solution Nos. 1 prepared with the compositions shown in Table 1. 3 (chitosan-containing coating solution) was used to coat the chitosan-containing layer. The coating was performed using a film coating apparatus high coater mini-type pan (Freund Sangyo Co., Ltd.) with the drying temperature of the coating apparatus kept constant (80 ° C.). The chitosan-containing layer was formed so that the chitosan mass relative to the capsule mass was about 1.7% by mass. A part of the produced capsule was extracted, and the composition of the chitosan layer was examined.
Next, the capsule coated with the chitosan layer was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass). A small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
参考例3で製造した大腸有用菌含有カプセルNo.3を、表1記載の組成で調製された溶液No.4(アルギン酸塩およびキトサン含有コーティング溶液)を用いて、キトサン含有層で被覆した。被覆は、フィルムコーティング装置ハイコーターミニ型パン(フロイント産業株式会社製)を用いて、コーティング装置の乾燥温度を一定(80℃)にして行った。カプセル質量に対するキトサン質量が約1.7質量%になるようにキトサン含有層を形成した。製造したカプセルの一部を抜き出し、キトサン層の組成を調べた。
次いで、キトサン層で被覆したカプセルをさらに腸溶性基材であるセラックで被覆した(カプセル質量に対して約1.2質量%)。得られたカプセルの表面にカルナウバロウを微量塗布し、多重コーティングカプセルを製造した。 <Production Example 10>
Capsule No. containing capsules useful in large intestine produced in Reference Example 3 3 were prepared using the solution No. 3 prepared with the composition shown in Table 1. 4 (alginate and chitosan-containing coating solution) was used to coat the chitosan-containing layer. The coating was performed using a film coating apparatus high coater mini-type pan (Freund Sangyo Co., Ltd.) with the drying temperature of the coating apparatus kept constant (80 ° C.). The chitosan-containing layer was formed so that the chitosan mass relative to the capsule mass was about 1.7% by mass. A part of the produced capsule was extracted, and the composition of the chitosan layer was examined.
Next, the capsule coated with the chitosan layer was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass). A small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
キトサン質量がカプセル質量に対して約0.5質量%になるようにした以外は、製造例7と同じ手順で大腸有用菌含有カプセルNo.1をキトサン含有層およびセラックで被覆し、多重コーティングカプセルを製造した。 <Production Example 11>
Capsule containing useful colons No. 1 in the same procedure as in Production Example 7 except that the mass of chitosan was about 0.5% by mass relative to the mass of the capsule. 1 was coated with a chitosan-containing layer and shellac to produce multi-coated capsules.
キトサン質量が約0.4質量%になるようにした以外は、製造例7と同じ手順で、大腸有用菌含有カプセルNo.1をキトサン含有層で被覆した。得られたカプセルの表面に、ゼイン被覆(カプセル質量に対して約0.3質量%)を施した。ゼイン被覆に用いたゼイン溶液は、ゼイン(小林ツエインDP(小林香料株式会社製))を6質量%濃度となるように60%エタノール溶液に溶解し、可塑剤としてグリセリン(花王株式会社製)をゼインに対し30質量%添加して調製した。次いで、キトサン層とゼインで被覆したカプセルをさらに腸溶性基材であるセラックで被覆した(カプセル質量に対して約1.2質量%)。得られたカプセルの表面にカルナウバロウを微量塗布し、多重コーティングカプセルを製造した。 <Production Example 12>
Except that the chitosan mass was about 0.4 mass%, the same procedure as in Production Example 7, 1 was coated with a chitosan-containing layer. A zein coating (about 0.3% by mass with respect to the capsule mass) was applied to the surface of the obtained capsule. The zein solution used for the zein coating was prepared by dissolving zein (Kobayashi Twein DP (manufactured by Kobayashi Fragrance Co., Ltd.)) in a 60% ethanol solution to a concentration of 6% by mass, and using glycerin (manufactured by Kao Corporation) as a plasticizer. It was prepared by adding 30% by mass to zein. Next, the capsule coated with the chitosan layer and zein was further coated with shellac as an enteric base material (about 1.2% by mass with respect to the capsule mass). A small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule.
(残存酢酸量・膜強度試験) 得られた各カプセルの一部を溶解し、残存酢酸量を、Inertsil ODS-4のカラムを用いたHPLCにて、別に準備した酢酸の標準溶液に対するピーク面積比として求めた。またカプセルの膜強度を、加圧式測定器(ミネベア株式会社製 荷重測定器)でカプセルが割れる圧力として測定した。 <Test Example 1>
(Residual acetic acid amount / membrane strength test) A part of each capsule obtained was dissolved, and the remaining acetic acid amount was measured by HPLC using an Inertsil ODS-4 column. As sought. The membrane strength of the capsules was measured as a pressure at which the capsules were broken with a pressurization type measuring device (load measuring device manufactured by Minebea Co., Ltd.).
製造例1~12の多重コーティングカプセルの胃、小腸、大腸での崩壊性を調べた。崩壊試験は、各カプセルを6個ずつ用い、日本薬局方の崩壊試験装置を用いて行った。
カプセルを、補助盤無しの条件で、pH1.2の溶液(胃想定液)中で60分間上下運動させ、崩壊したカプセルは取り除き、続いてpH6.8の溶液(小腸想定液)中で120分間上下運動させ、崩壊したカプセルは取り除き、その後、補助盤を用いた条件で、pH3.5の溶液(大腸想定液)中で120分間上下運動させた。各溶液中でのカプセルの崩壊性を下記評価基準に従って3段階で判定した。
-評価基準-(胃想定液、小腸想定液中での崩壊性)
A:6個すべてが形状を維持し、膨潤や崩壊などの変形が認められなかった(適合)
B:6個中で膨潤または変形があるが、崩壊は累計2個以内である(適合)
C:6個中累計3個以上で崩壊が認められる(不適)
-評価基準-(大腸想定液中での崩壊性)
A:6個すべてが試験され、すべてが大腸想定液中で崩壊(適合)
B:6個中5個以上が試験され、すべてが大腸想定液中で崩壊(適合)
C:6個中5個以上が試験され、崩壊しないカプセルがある(不適)
実施せず:6個中4個以下しか試験できない場合(不適) (Disintegration test)
The disintegration properties of the multi-coated capsules of Production Examples 1 to 12 in the stomach, small intestine and large intestine were examined. The disintegration test was performed using 6 capsules each and using a disintegration test apparatus of Japanese Pharmacopoeia.
The capsule is moved up and down in a pH 1.2 solution (stomach solution) for 60 minutes without an auxiliary board, the disintegrated capsule is removed, and then in a pH 6.8 solution (small intestine solution) for 120 minutes. The capsule which collapsed was moved up and down, the disintegrated capsule was removed, and then moved up and down for 120 minutes in a pH 3.5 solution (large intestine assumed liquid) under the condition using an auxiliary board. The disintegration properties of the capsules in each solution were determined in three stages according to the following evaluation criteria.
-Evaluation criteria- (Disintegration in assumed stomach and small intestine fluids)
A: All six maintained their shape, and no deformation such as swelling or collapse was observed (conformity)
B: There is swelling or deformation in 6 pieces, but the total number of collapses is 2 or less (conformity)
C: Collapse is observed in 3 or more out of 6 (unsuitable)
-Evaluation criteria- (disintegration in the assumed large intestine fluid)
A: All 6 were tested and all collapsed in the assumed colon fluid (adapted)
B: 5 or more of 6 were tested, and all collapsed in the assumed large intestine fluid (adapted)
C: 5 or more of 6 were tested, and some capsules did not collapse (unsuitable)
Not implemented: When only 4 or less of 6 can be tested (unsuitable)
アルギン酸を含有したキトサン層で被覆された製造例10のカプセルは、小腸想定液中でカプセルが崩壊し、大腸までカプセル内の物質を送達できないことが分かった。
キトサン層の厚さが薄くなると、胃や小腸の想定液でのカプセルの崩壊耐性が低下した。さらにキトサン層の厚さがカプセルに対し0.5質量%未満になると、大腸想定液試験前にカプセルが崩壊した(製造例11~12)。 The evaluation results are shown in Table 2. Capsules containing alginic acid and calcium salt in the capsules of Production Examples 1 to 2, 4 to 5 and 7 to 8 and coated with a chitosan-containing layer have high membrane strength, and disintegration in the assumed solution of the stomach and small intestine While it was highly resistant, it disintegrated well in the assumed large intestine. In addition, the capsules of Production Examples 1 and 2 coated with a layer containing chitosan and zein further improved the resistance to disintegration in the assumed liquid of the stomach and small intestine, and the amount of acid remaining in the chitosan-containing layer decreased. . In Production Examples 3, 6, and 9 in which the capsule did not contain alginic acid and calcium salt, the disintegration resistance in the stomach and small intestine assumed liquid decreased, and many capsules disintegrated before the large intestine assumed liquid test. In the capsule of Production Example 3, in Test Example 2 to be described later, it was suggested that the liquid entered the capsule in the assumed small intestine solution.
The capsule of Production Example 10 coated with a chitosan layer containing alginic acid was found to be unable to deliver the substance in the capsule to the large intestine because the capsule collapsed in the assumed small intestine solution.
When the thickness of the chitosan layer was reduced, the capsule disintegration resistance in the assumed solution of the stomach and small intestine decreased. Further, when the thickness of the chitosan layer was less than 0.5% by mass with respect to the capsule, the capsule collapsed before the test for the assumed large intestine solution (Production Examples 11 to 12).
製造例1、3、4、6、7および9の多重コーティングカプセルを用いて、胃想定液浸漬後でのカプセル内ビフィズス菌の残存生菌数を調べた。pH1.2の胃想定液中で、試験例1と同様に60分間崩壊試験を行い、崩壊せずに残ったカプセルについて、内部のビフィズス菌の残存菌数を計測した。残存菌数は、カプセルより取り出した内容粉末を希釈液中に懸濁し、無菌的に希釈法により所定濃度まで希釈した後、この菌液を嫌気性培地であるBL寒天培地の表面に接種し嫌気培養し、菌数を計測した。
さらに、製造例1および3のカプセルについて、pH1.2の胃想定液中で60分間崩壊試験を行った後、pH6.8の小腸想定液中で120分間崩壊試験を行い、同様に菌数を計測した。
結果を表3に示す。カプセル内にアルギン酸とカルシウム塩を含有し且つキトサン含有層で被覆された製造例1、4、7のカプセルは、耐水性、耐酸性があり、ビフィズス菌の残存も高かった。カプセル内にアルギン酸とカルシウム塩を充填し、且つキトサンーゼイン層で被覆された製造例1では、生菌数の減少がほとんどなかった。キトサンーゼイン層被覆を有するがカプセル内にアルギン酸とカルシウム塩を含有していない製造例3のカプセルは、胃想定液での試験後には高い生菌数を保持していたが、小腸想定液での試験後には生菌数が大幅に低下していた。 <Test Example 2>
Using the multi-coated capsules of Production Examples 1, 3, 4, 6, 7, and 9, the remaining viable count of bifidobacteria in the capsule after immersion in the assumed gastric fluid was examined. A disintegration test was carried out for 60 minutes in the assumed gastric fluid at pH 1.2 in the same manner as in Test Example 1, and the number of remaining bifidobacteria in the capsule was measured for the capsules that remained undisintegrated. The number of remaining bacteria is determined by suspending the powder extracted from the capsule in a dilute solution, aseptically diluting it to a predetermined concentration by a dilution method, and then inoculating this bacterial solution on the surface of the anaerobic BL agar medium. After culturing, the number of bacteria was counted.
Furthermore, about the capsule of manufacture example 1 and 3, after performing the disintegration test for 60 minutes in the gastric liquid of pH1.2, the disintegration test is performed for 120 minutes in the small intestine of pH6.8, and the number of bacteria is similarly measured. Measured.
The results are shown in Table 3. The capsules of Production Examples 1, 4, and 7 containing alginic acid and a calcium salt in the capsule and coated with a chitosan-containing layer had water resistance and acid resistance, and the bifidobacteria remained high. In Production Example 1 in which the capsule was filled with alginic acid and calcium salt and coated with a chitosan-zein layer, there was almost no decrease in the number of viable bacteria. The capsule of Production Example 3 having a chitosan-zein layer coating but containing no alginic acid and calcium salt in the capsule maintained a high viable count after the test with the assumed gastric solution, but the test with the assumed small intestine solution Later, the number of viable bacteria decreased significantly.
参考例1の大腸有用菌含有カプセル(カプセルNo.1)のカプセルを用いて、ゼインの添加量について確認した。表4記載の組成で調製されたキトサン-ゼイン含有コーティング溶液を用いて、キトサン-ゼイン層で被覆した。被覆は、フィルムコーティング装置ハイコーターミニ型パン(フロイント産業株式会社製)を用いて、コーティング装置の乾燥温度を一定(65℃)にして行った。カプセル質量に対するキトサン質量が約1.4質量%になるようにキトサン-ゼイン層を形成した。次いで、キトサン-ゼイン層で被覆したカプセルをさらに耐酸性基材であるセラックで被覆した(カプセル質量に対して約1.2質量%)。得られたカプセルの表面にカルナウバロウを微量塗布し、多重コーティングカプセルを製造した。製造した各カプセルを試験例1と同様の手順で評価した。結果を表5に示す。なお、製造例18は、コーティング溶液に沈殿物が発生したため、試験を実施しなかった。 <Test Example 3>
Using the capsule of useful colon-containing bacteria (capsule No. 1) of Reference Example 1, the amount of zein added was confirmed. A chitosan-zein-containing coating solution prepared with the composition described in Table 4 was used to coat the chitosan-zein layer. The coating was performed using a film coater high coater mini-type pan (Freund Sangyo Co., Ltd.) at a constant drying temperature (65 ° C.). The chitosan-zein layer was formed so that the chitosan mass relative to the capsule mass was about 1.4% by mass. Next, the capsule coated with the chitosan-zein layer was further coated with shellac, which is an acid-resistant substrate (about 1.2% by mass with respect to the capsule mass). A small amount of Carnauba wax was applied to the surface of the obtained capsule to produce a multi-coated capsule. Each manufactured capsule was evaluated in the same procedure as in Test Example 1. The results are shown in Table 5. In Production Example 18, a test was not performed because a precipitate was generated in the coating solution.
参考例1の大腸有用菌含有カプセル(カプセルNo.1)のカプセルを用いて、キトサン含有層の厚さがカプセル崩壊性に与える影響について確認した。キトサン含有層でのキトサン質量がカプセル質量に対して表6記載の値になるようにした以外は、製造例7と同じ手順で大腸有用菌含有カプセルNo.1をキトサン含有層およびセラックで被覆し、多重コーティングカプセルを製造した。製造した各カプセルを試験例1と同様の手順で評価した。結果を表7に示す。なお、表6、7には、製造例7および製造例11の例を再掲する。
キトサン含有層が厚くなると、胃および小腸想定液での崩壊耐性が向上した。一方、キトサン含有層の厚さが増すに従って、層形成時の乾燥時間が増大した。特に製造例19では乾燥に時間がかかったため、加熱によるカプセル内のビフィズス菌の残存率の低下のおそれがあった。 <Test Example 4>
Using the capsule of useful colon-containing bacteria (capsule No. 1) of Reference Example 1, the effect of the thickness of the chitosan-containing layer on the capsule disintegration property was confirmed. Capsule containing useful colons No. 1 in the same procedure as in Production Example 7 except that the chitosan mass in the chitosan-containing layer was adjusted to the value described in Table 6 with respect to the capsule mass. 1 was coated with a chitosan-containing layer and shellac to produce multi-coated capsules. Each manufactured capsule was evaluated in the same procedure as in Test Example 1. The results are shown in Table 7. Tables 6 and 7 show examples of Production Example 7 and Production Example 11 again.
When the chitosan-containing layer was thickened, the resistance to disintegration in the stomach and small intestine assumed liquid was improved. On the other hand, as the thickness of the chitosan-containing layer increased, the drying time during layer formation increased. In particular, in Production Example 19, since it took time to dry, there was a fear that the residual rate of bifidobacteria in the capsule was reduced by heating.
Claims (12)
- 大腸有用菌、アルギン酸およびカルシウム塩を内包するカプセルと、当該カプセルを被覆するキトサン含有層と、当該キトサン含有層を被覆する腸溶性基材含有層とを含み、該キトサン含有層におけるキトサン質量が該カプセルの質量に対して0.5質量%~8.0質量%である、大腸送達用組成物。 A capsule containing a colonic fungus, alginic acid and calcium salt; a chitosan-containing layer covering the capsule; and an enteric substrate-containing layer covering the chitosan-containing layer, wherein the chitosan mass in the chitosan-containing layer is A composition for delivery to the large intestine, which is 0.5% by mass to 8.0% by mass with respect to the mass of the capsule.
- 前記キトサン含有層が、キトサンおよびゼインを含有する層である、請求項1記載の組成物。 The composition according to claim 1, wherein the chitosan-containing layer is a layer containing chitosan and zein.
- 前記キトサンおよびゼインを含有する層において、該ゼインの含有量が該キトサン100質量部に対して0.5質量部~100質量部である、請求項2記載の組成物。 3. The composition according to claim 2, wherein in the layer containing chitosan and zein, the content of zein is 0.5 to 100 parts by mass with respect to 100 parts by mass of chitosan.
- 前記アルギン酸が、アルギン酸、アルギン酸塩およびアルギン酸のエステルからなる群より選択される少なくとも1種である、請求項1~3のいずれか1項記載の組成物。 The composition according to any one of claims 1 to 3, wherein the alginic acid is at least one selected from the group consisting of alginic acid, alginates and esters of alginic acid.
- 前記カプセルに内包される前記アルギン酸の量が、該カプセル内の充填物中0.1質量%~20質量%であり、且つ該カプセルに内包される前記カルシウム塩の量が、該アルギン酸100質量部に対して2質量部~40質量部である、請求項1~4のいずれか1項記載の組成物。 The amount of the alginic acid contained in the capsule is 0.1% by mass to 20% by mass in the filling in the capsule, and the amount of the calcium salt contained in the capsule is 100 parts by mass of the alginic acid. The composition according to any one of claims 1 to 4, wherein the composition is 2 to 40 parts by mass with respect to the total amount.
- 前記腸溶性基材含有層の量が、該層中の腸溶性基材の質量換算で、前記カプセルの質量に対して0.5質量%~10.0質量%である、請求項1~5のいずれか1項記載の組成物。 The amount of the enteric base material-containing layer is 0.5% by mass to 10.0% by mass with respect to the mass of the capsule in terms of mass of the enteric base material in the layer. The composition of any one of these.
- 大腸有用菌、アルギン酸およびカルシウム塩を内包するカプセルを準備すること;
該カプセルをキトサン含有層で被覆すること;ならびに
該キトサン含有層で被覆したカプセルを、さらに腸溶性基材含有層で被覆すること、
を含む大腸送達用組成物の製造方法であって、
該キトサン含有層におけるキトサン質量が該カプセルの質量に対して0.5質量%~8.0質量%である、方法。 Preparing capsules containing useful colonic bacteria, alginic acid and calcium salt;
Coating the capsule with a chitosan-containing layer; and further coating the capsule coated with the chitosan-containing layer with an enteric substrate-containing layer;
A method for producing a composition for large intestine delivery comprising:
The method wherein the chitosan mass in the chitosan-containing layer is 0.5 mass% to 8.0 mass% with respect to the mass of the capsule. - 前記キトサン含有層が、キトサンおよびゼインを含有する層である、請求項7記載の方法。 The method according to claim 7, wherein the chitosan-containing layer is a layer containing chitosan and zein.
- 前記キトサンおよびゼインを含有する層において、該ゼインの含有量が該キトサン100質量部に対して0.5質量部~100質量部である、請求項8記載の方法。 The method according to claim 8, wherein in the layer containing chitosan and zein, the content of the zein is 0.5 to 100 parts by mass with respect to 100 parts by mass of the chitosan.
- 前記アルギン酸が、アルギン酸、アルギン酸塩およびアルギン酸のエステルからなる群より選択される少なくとも1種である、請求項7~9のいずれか1項記載の方法。 The method according to any one of claims 7 to 9, wherein the alginic acid is at least one selected from the group consisting of alginic acid, alginates and esters of alginic acid.
- 前記カプセルに内包される前記アルギン酸の量が、該カプセル内の充填物中0.1質量%~20質量%であり、且つ該カプセルに内包される前記カルシウム塩の量が、該アルギン酸100質量部に対して2質量部~40質量部である、請求項7~10のいずれか1項記載の方法。 The amount of the alginic acid contained in the capsule is 0.1% by mass to 20% by mass in the filling in the capsule, and the amount of the calcium salt contained in the capsule is 100 parts by mass of the alginic acid. The method according to any one of claims 7 to 10, wherein the amount is from 2 to 40 parts by weight based on the weight.
- 前記腸溶性基材含有層の量が、該層中の腸溶性基材の質量換算で、前記カプセルの質量に対して0.5質量%~10.0質量%である、請求項7~11のいずれか1項記載の方法。 The amount of the enteric base material-containing layer is 0.5% by mass to 10.0% by mass with respect to the mass of the capsule in terms of mass of the enteric base material in the layer. The method of any one of these.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013547038A JP5496432B1 (en) | 2012-12-21 | 2013-05-17 | Large intestine delivery capsule and method for producing the same |
KR1020157016444A KR20150100682A (en) | 2012-12-21 | 2013-05-17 | Colon delivery capsule and method for producing same |
CN201380066998.9A CN104968356A (en) | 2012-12-21 | 2013-05-17 | Colon delivery capsule and method for producing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-279945 | 2012-12-21 | ||
JP2012279945 | 2012-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014097664A1 true WO2014097664A1 (en) | 2014-06-26 |
Family
ID=50978020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/063748 WO2014097664A1 (en) | 2012-12-21 | 2013-05-17 | Colon delivery capsule and method for producing same |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP5588078B2 (en) |
KR (1) | KR20150100682A (en) |
CN (1) | CN104968356A (en) |
TW (1) | TWI584824B (en) |
WO (1) | WO2014097664A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111867583A (en) * | 2018-01-18 | 2020-10-30 | 学校法人庆应义塾 | Capsule for treating ulcerative colitis |
CN112295514A (en) * | 2020-10-29 | 2021-02-02 | 湖北工业大学 | Preparation method and application of core-shell structure microcapsule particles |
JP2021014422A (en) * | 2019-07-11 | 2021-02-12 | 日清ファルマ株式会社 | Fecal state improving agent |
JP2021014421A (en) * | 2019-07-11 | 2021-02-12 | 日清ファルマ株式会社 | Qol improving agent |
JP6944036B1 (en) * | 2020-11-05 | 2021-10-06 | 株式会社ファンケル | Hard capsule formulation |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6457963B2 (en) * | 2016-02-25 | 2019-01-23 | 日清ファルマ株式会社 | Large intestine delivery capsule formulation |
JP7331322B2 (en) * | 2017-11-03 | 2023-08-23 | ディーエスエム アイピー アセッツ ビー.ブイ. | novel delivery system |
CA3139731A1 (en) | 2019-06-14 | 2020-12-17 | Takehiro Nishikawa | Delayed disintegration-type capsule and method for producing same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59220175A (en) * | 1983-05-28 | 1984-12-11 | Furointo Sangyo Kk | Coating of health food |
JPS63101319A (en) * | 1986-10-15 | 1988-05-06 | Kanebo Ltd | Production of enteric drug preparation |
JP2000063289A (en) * | 1998-08-20 | 2000-02-29 | Morinaga Milk Ind Co Ltd | Pharmaceutical preparation containing physiologically active substance |
WO2001010467A1 (en) * | 1999-08-09 | 2001-02-15 | Dainippon Pharmaceutical Co., Ltd. | Solid preparations containing chitosan powder and process for producing the same |
JP2012149032A (en) * | 2010-12-28 | 2012-08-09 | Freund Corp | Capsule for delivering bifidobacterium into large intestine, and method for producing the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5496616B2 (en) * | 2009-11-18 | 2014-05-21 | フロイント産業株式会社 | Colorectal drug delivery system formulation |
JP5102401B1 (en) * | 2012-03-30 | 2012-12-19 | 森下仁丹株式会社 | Large intestine specific disintegration capsule |
-
2013
- 2013-05-17 CN CN201380066998.9A patent/CN104968356A/en active Pending
- 2013-05-17 KR KR1020157016444A patent/KR20150100682A/en not_active Application Discontinuation
- 2013-05-17 WO PCT/JP2013/063748 patent/WO2014097664A1/en active Application Filing
- 2013-05-17 TW TW102117501A patent/TWI584824B/en active
-
2014
- 2014-03-04 JP JP2014041118A patent/JP5588078B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59220175A (en) * | 1983-05-28 | 1984-12-11 | Furointo Sangyo Kk | Coating of health food |
JPS63101319A (en) * | 1986-10-15 | 1988-05-06 | Kanebo Ltd | Production of enteric drug preparation |
JP2000063289A (en) * | 1998-08-20 | 2000-02-29 | Morinaga Milk Ind Co Ltd | Pharmaceutical preparation containing physiologically active substance |
WO2001010467A1 (en) * | 1999-08-09 | 2001-02-15 | Dainippon Pharmaceutical Co., Ltd. | Solid preparations containing chitosan powder and process for producing the same |
JP2012149032A (en) * | 2010-12-28 | 2012-08-09 | Freund Corp | Capsule for delivering bifidobacterium into large intestine, and method for producing the same |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111867583A (en) * | 2018-01-18 | 2020-10-30 | 学校法人庆应义塾 | Capsule for treating ulcerative colitis |
JP2021014422A (en) * | 2019-07-11 | 2021-02-12 | 日清ファルマ株式会社 | Fecal state improving agent |
JP2021014421A (en) * | 2019-07-11 | 2021-02-12 | 日清ファルマ株式会社 | Qol improving agent |
CN112295514A (en) * | 2020-10-29 | 2021-02-02 | 湖北工业大学 | Preparation method and application of core-shell structure microcapsule particles |
CN112295514B (en) * | 2020-10-29 | 2023-04-07 | 湖北工业大学 | Preparation method and application of core-shell structure microcapsule particles |
JP6944036B1 (en) * | 2020-11-05 | 2021-10-06 | 株式会社ファンケル | Hard capsule formulation |
JP2022074974A (en) * | 2020-11-05 | 2022-05-18 | 株式会社ファンケル | Hard capsule formulation |
Also Published As
Publication number | Publication date |
---|---|
JP2014139200A (en) | 2014-07-31 |
TWI584824B (en) | 2017-06-01 |
JP5588078B2 (en) | 2014-09-10 |
TW201424774A (en) | 2014-07-01 |
KR20150100682A (en) | 2015-09-02 |
CN104968356A (en) | 2015-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5588078B2 (en) | Large intestine delivery capsule and method for producing the same | |
JP3752421B2 (en) | Fine enteric coated granules for stabilization of lactic acid bacteria | |
ES2957783T3 (en) | Protection of microbial cells against acid degradation | |
JP5203217B2 (en) | Pharmaceutical compositions and methods for treating or preventing oxalate-related diseases | |
EP2179727B1 (en) | Water insoluble polymer: modified starch derivative-based film coatings for colon targeting | |
JP5087167B2 (en) | Bifidobacterium large intestine delivery capsule and method for producing the same | |
AU2012210575A1 (en) | Protection of microbial cells from acidic degradation | |
JP6062802B2 (en) | Chitosan-containing composition and chitosan coating composition | |
JP5997034B2 (en) | Chitosan-containing composition and chitosan coating composition | |
JP6457963B2 (en) | Large intestine delivery capsule formulation | |
JP5496432B1 (en) | Large intestine delivery capsule and method for producing the same | |
JP5907796B2 (en) | Intestinal environment improving food | |
KR20020063978A (en) | Lactic acid bacteria-containing microgranular composition for enteric delivery and process for the preparation thereof | |
JP5940869B2 (en) | Intestinal environment-improved dry-coated tablets and hard capsules | |
JP5957280B2 (en) | Large intestine delivery seamless capsule preparation and method for producing the same | |
US20210401900A1 (en) | Enteric composition, food or beverage product containing the same, method for controlling disintegration time of the same, and method for manufacturing the same | |
JP2003012526A (en) | Pharmaceutical preparation including useful live bacterium | |
TW202007400A (en) | product | |
JP6944036B1 (en) | Hard capsule formulation | |
CN117257845A (en) | Method for targeted delivery of live probiotics | |
JP2021014421A (en) | Qol improving agent | |
JP2023019150A (en) | Hard capsule formulation and powder composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2013547038 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13865550 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20157016444 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13865550 Country of ref document: EP Kind code of ref document: A1 |